JAK2-IN-6
JAK2-IN-6, a multiple-substituted aminothiazole derivative, is a potent and selective JAK2 inhibitor with an IC50 of 22.86 μg/mL. JAK2-IN-6 shows no activity against JAK1 and JAK3. JAK2-IN-6 has anti-proliferative effect against cancer cells[1].
Product Specifications
CAS Number
[353512-04-6]
UNSPSC
12352005
Target
JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/jak2-in-6.html
Purity
97.07
Solubility
DMSO : 60 mg/mL (ultrasonic; adjust pH to 5 with HCl)
Smiles
O=C(C1=C(N)N=C(NC2=CC=CC=C2)S1)C3=CC=C(Cl)S3
Molecular Formula
C14H10ClN3OS2
Molecular Weight
335.84
References & Citations
[1]Ting-Ting Yao, et al. Integration of pharmacophore mapping and molecular docking in sequential virtual screening: towards the discovery of novel JAK2 inhibitors. RSC Adv., 2017, 7, 10353-10360.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
JAK2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6153149-01 0.1 mL
JARID1A (Jumonji/ARID Domain-containing Protein 1A, Retinoblastoma-binding Protein 2, RBBP-2, JARID1A, RBBP2, RBP2, KDM5A) (HRP)
Ask
View Details 
MBS6153149-02 5x 0.1 mL
JARID1A (Jumonji/ARID Domain-containing Protein 1A, Retinoblastoma-binding Protein 2, RBBP-2, JARID1A, RBBP2, RBP2, KDM5A) (HRP)
Ask
View Details